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ABSTRACT 
Purpose: Health services across the world utilise advanced practice in cancer care. In the UK, lung 
cancer nurse specialists (LCNS) are recognised as key components of quality care in national 
guidelines, yet access to LCNS contact is unequal and some responsibilities are reportedly left 
undone. We assess whether any variation in working practices of LCNS is attributable to factors of 
the lung cancer service at the hospital trust. 
Method: Nationwide workload analysis of LCNS working practices in England, linked at trust level to 
patient data from the National Lung Cancer Audit. Chi-squared tests were performed to assess 
whether patient contact, workload, involvement in multidisciplinary teams (MDT), and provision of 
key interventions were related to 1) the trust's lung cancer service size, 2) LCNS caseload, 3) anti-
cancer treatment facilities and 4) lung cancer patient survival. 
Results: Unpaid overtime was substantial for over 60% of nurses and not associated with particular 
service factors assessed; lack of administrative support was associated with large caseloads and 
chemotherapy facilities. LCNS at trusts with no specialty were more likely to challenge all MDT 
members (80%) compared with those at surgical (53%) or chemotherapy (58%) trusts. The most 
frequent specialist nursing intervention to not be routinely offered was proactive case management. 
Conclusion: Working practices of LCNS vary according to service factors, most frequently associated 
with trust anti-cancer treatment facilities. High workload pressures and limited ability to provide key 
interventions should be addressed across all services to ensure patients have access to 
recommended standards of care. 
Keywords:  Case management, Clinical Audit, Lung Neoplasms, Nurse Specialists, Survey, Workload  
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1. INTRODUCTION  
The unmatched skillset of nurses in advanced practice is increasingly recognised internationally (de 
Bont et al., 2016, Steinke et al., 2017). In the UK, clinical nurse specialists are linked to better 
outcomes for both patients and the local health economies as experienced practitioners providing 
quality care, leadership and enabling safe release of consultant time (NCAT, 2010, Read and Waters, 
2015). Cancer care represents a significant specialist area: particularly lung cancer which accounts 
for 22% of all cancer deaths in the UK (CRUK, 2014), and studies have shown poor five-year relative 
survival rates compared with other European countries (De Angelis et al., 2014, Francisci et al., 
2015).  
Patients and their families gain enormous value from the crucial role lung cancer nurse specialists 
(LCNS) have throughout the clinical pathway, from breaking significant news to meeting information 
needs, advocating patient wishes and offering a continuity of care (McPhillips et al., 2014, 
Mishelmovich et al., 2016, Tod et al., 2015, White, 2013). As financial pressures on health services 
continue, there have been gains in productivity and cost-effectiveness resulting from LCNS working 
with people to proactively manage their condition in limiting the progression of disease burden 
(Baxter and Leary, 2011, Leary and Baxter, 2014).  
The Department of Health (England) recommends that specialist nurses should be available 
throughout the cancer journey and the National Cancer Action Team (NCAT) recognised the unique 
insight LCNS can provide in multi-disciplinary teams (MDT)(NCAT, 2011). As such, the LUCADA 
dataset of the National Lung Cancer Audit (NLCA) includes non-mandatory records of initial contact 
and timing of assessments by LCNS, though data completeness varied between 2007 and 2011; 
assessment records were missing for 32% and 10% of people, respectively (Khakwani et al., 2016). 
With limitations to LCNS metrics considered, the NLCA reports inequalities in access to LCNS 
workforces between services and that hospital trusts do not always meet the standard of at least 
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80% of patients seen by a LCNS (RCP, 2015). National audit data has also shown that people 
diagnosed in trusts with high annual numbers of new patients are less likely to have an initial LCNS 
assessment whereas those with early stage lung cancer are more likely to be assessed (Khakwani et 
al., 2016). Whilst there is some recognition for the local cultures and practices that seek to minimise 
such differences, a recent census of the cancer nurse specialist workforce identified variability in 
vacancies and caseload (Macmillan, 2017), potentially impacting on the depth and quality of 
subsequent contact. A survey of 78 LCNS indicated that the majority felt that important work, most 
often proactive case management, was left undone against best practice (Leary et al., 2014). 
We linked insights provided by a nationwide workload survey of 230 LCNS in England to data from 
the NCAT workforce census and NLCA data from over 125,000 patients diagnosed between 2007 and 
2011 to build a comprehensive view of specialist cancer nurse experiences according to factors that 
described the lung cancer service in which they work.  Our aim was to assess whether LCNS 
workforce, workload, MDT activity and the ability to provide key advanced nursing interventions 
varied according to the service size, caseload, onsite provision of anti-cancer treatments, and patient 
survival. Where we identify gaps and barriers to delivering the LCNS role, we highlight strategies to 
improve resource allocation.  
2. METHODS 
2.1. Study population and data sources 
We used linked data to capture information on people with lung cancer in England and the LCNS 
workforce across English National Health Service (NHS) trusts (i.e. all hospitals providing lung cancer 
services across the country). To obtain details of LCNS (including thoracic nurse specialist) working 
practices across the patient care pathway, we designed a survey disseminated via the National Lung 
Cancer Forum for Nurses (NLCFN) using Survey Monkey in 2014 (Appendix A). Using the NHS hospital 
trust code where the LCNS worked, survey data was linked with clinical information from the English 
NLCA according to hospital where patients first seen, Hospital Episode Statistics (HES) in-patient 
4 
 
data, Office for National Statistics (ONS) mortality data, and with the 2011 NCAT LCNS workforce 
census in England (NCAT, 2012). 
We categorised each trust according to size, LCNS caseload, anti-cancer treatment facilities and 
survival of its lung cancer patient population. Trust size was measured using NLCA data between 
2007 and 2011 to calculate the average number of new lung cancer patients seen annually in each 
trust, as previously described (Khakwani et al., 2016). Size category of hospital trust was defined: 
small (<175), medium (175-264), large (≥265). Patients first seen in 2011 plus surviving patients since 
2004 were divided by the number of whole time equivalent (WTE) LCNS at a trust to estimate each 
trust’s total caseload per LCNS (Khakwani et al., 2016). Caseload was calculated using the 
assumption that patients first seen in a particular trust were equally divided between the trust’s 
LCNS team, and remained at that trust throughout the pathway. Trusts were divided into 2 groups 
based on whether or not they were above the median caseload of 188 patients per LCNS. NLCA and 
HES data were used to classify trusts according to whether surgery was available (with or without 
chemotherapy), only chemotherapy was available, or neither treatment facilities were available 
onsite. A chemotherapy trust was defined by at least 75% of patients receiving an anti-cancer drug 
at a trust also being first seen there (Powell et al., 2014). To categorise trusts based on the survival 
of their lung cancer patient population we used median survival information based on ONS date of 
death for patients first seen in a trust in 2014 (RCP, 2015). The hazard ratio for death following 
diagnosis was calculated for each trust’s patient population compared with the national lung cancer 
population, adjusting for sex, age, stage, performance status and socioeconomic group. Trusts were 
categorised as having either average/higher (hazard ratio≤1) or lower (hazard ratio>1) survival 
compared with the national English lung cancer population. 
We used salary and WTE information from the linked NCAT census to calculate the composition of 
each trust’s LCNS team, categorising each LCNS as band 6, 7 or 8. Detailed information on workload 
and working practices of the hospital trusts LCNS workforce were then obtained from the NLCFN 
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survey. The workload survey requested contractual and estimated weekly overtime hours which we 
used to calculate the proportion of WTE hours working overtime. Hours of weekly administrative 
support as reported by the LCNS were grouped as no support, up to 10 hours, or >10 hours. The 
survey requested each LCNS to report the point on the patient care pathway at which they first see 
more than 60% of patients, with answers summarised as before/at or after the lung cancer 
diagnosis. An estimation of the proportion of new patients seen as emergency presentations was 
also requested as this is often indicative of a greater severity of disease manifestation. LCNS are 
considered core members of the lung cancer MDT (NCAT, 2011, NICE, 2011), so the survey 
ascertained whether they actively attended the MDT, whether they were prepared to challenge all 
other members of the MDT, and whether they felt uncomfortable or intimidated within the MDT 
setting. The survey also captured LCNS ability to provide key interventions that are accepted as part 
of the LCNS role (Baxter and Leary, 2011, Leary and Baxter, 2014, Tod et al., 2015, White, 2013). 
Respondents were asked which interventions they were routinely able to offer (i.e. to more than 
70% of their patients) at each of the following points of the clinical care pathway: before diagnosis, 
at diagnosis, post diagnosis, treatment, end of treatment, follow-up, disease progression, and end of 
life care. 
2.2. Statistical analyses  
We assessed how representative the trusts included in our study were of all English trusts by 
comparing their treatment facilities, LCNS salary band composition and caseload size. Survey 
responses regarding LCNS workforce, patient contact, workloads and MDT experience were 
described as proportions of LCNS survey responses (i.e. the English LCNS workforce captured by the 
NLCFN survey). Responses on the ability to offer key interventions were aggregated to trust level 
using the rationale that one affirmation of provision was sufficient to indicate it as being offered by 
the trust’s LCNS team. Variations in reported provision between LCNS at a trust may also be 
influenced by individual patient-contact patterns across the pathway; trust-level aggregation 
provided the best description of key interventions available to the patient population. Provision was 
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assessed at any point of the pathway and then specifically at diagnosis, follow-up (stable disease), 
and disease progression based on the relative importance of a LCNS offering interventions at these 
times, compared with other specialist nurses who may be involved at different pathway points 
(Gardiner et al., 2011, NCAT, 2010, NICE, 2004). 
Chi-squared tests were performed to determine whether differences in LCNS patient contact, 
workload, experience of MDT meetings and capacity to routinely offer interventions were associated 
with trust size, LCNS caseload, anti-cancer treatment facilities or one-year survival. To assess 
potential response bias we used chi-squared tests to assess whether missing data on survey 
responses was related to the four trust factors. A level of 0.05 for statistical significance was used 
throughout. Data analyses were performed using Stata SE14. 
3. RESULTS 
A total of 281 responses were collected from LCNS across the UK. Responses from Wales, Scotland, 
Northern Ireland, and private healthcare institutions were subsequently excluded from this study as 
linkage was only available with the English NLCA and NCAT data, leaving 230 LCNS (providing 199.7 
WTE positions) at 105 NHS hospital trusts. Our survey therefore covered 75.8% of WTE LCNS 
positions and 69.5% of acute trusts across England (Macmillan, 2014, RCP, 2015). Statistical analysis 
showed no association with trust inclusion or exclusion according to the treatment facilities, LCNS 
workforce composition, or LCNS caseload (Supplementary Table 1). Survey response completeness 
for specific questions ranged from 75.6% (In the last year what proportion of your new patients do 
you estimate you see as emergency presentations?) to 100% (How many hours of administrative 
support do you have per week?) and was similar across trust factors (Supplementary Table 2). 
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Figure 1: LCNS survey responses on patient contact, workload and MDT experience (N=230 LCNS 
responses across England) 
Figure 1 shows the proportion of nurse responses that report a particular working practice in the workload 
survey (N=230). LCNS – lung cancer nurse specialist; LC – lung cancer; MDT – multidisciplinary team; inc. – 
included. Percentages do not add up to 100% because of missing data: based on α-195 responses β-174 
responses γ-225 responses δ-190 responses. Patient contact – dark bars, workload – light bars, MDT 
experience – lightest bars. 
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3.1. Overview of workforce, workload and working practices across English hospital trusts 
Figure 1 provides an overview of LCNS survey responses across all trusts represented. Most 
respondents were at trusts comprising teams of Band-7-only LCNS (45.7%), whilst the smallest 
proportion of respondents were from teams that included Band 8 LCNS (17.4%). Most respondents 
(73.9%) indicated that their first contact with the majority of patients was before or at diagnosis and 
33.9% reported that more than 20% of their new cases presented as emergencies. With regards to 
workload, 63.5% reported additionally working over 10% of their weekly hours as overtime and 
63.5% reported no administrative support. The majority of respondents (77.8%) had active MDT 
attendance yet only 51.7% said they would challenge any MDT members and 19.1% found the MDT 
uncomfortable or intimidating. Two out of nine key interventions (meeting information needs and 
managing symptom control) were routinely offered by all trusts at some point of the pathway 
(Figure 2A); this was reported to be slightly lower at diagnosis, follow-up and/or disease progression 
(offered in 93% and 96% of trusts respectively) (Figure 2B). Conversely, LCNS teams could not 
routinely offer proactive case management (defined here as regular contact with patients to identify 
problems earlier) or holistic needs assessment (HNA, defined here as assessing the disease burden 
and patient needs as a whole) at 17% and 9% of trusts respectively which was higher (31% and 17%) 
at the important pathway points (Figure 2). Although prevalence of key intervention provision 
varied, there were no statistically significant associations between routine provision of these key 
interventions at diagnosis, follow-up or at disease progression according to the trust’s service size, 
LCNS caseload, treatment facilities or lung cancer patient survival (Table 1; Supplementary Table 3). 
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Figure 2:   Number of hospital trusts routinely offering key LCNS workforce interventions (N=100 
hospital trusts) 
Figure 2 shows the number of trusts that can or cannot routinely offer a key nursing intervention to patients 
(N=100), based on at least one LCNS within the workforce indicating provision at A) any point of the cancer 
pathway and B) specific pathway points of diagnosis, follow-up (stable disease) and/or disease progression. 
Routinely offered was defined as provided to more than 70% of patients. Dark bars– not routinely offered by 
LCNS at trust, light bars – routinely offered by LCNS at trust. 
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Table 1: Key interventions not routinely offered by hospital trusts at specific pathway points of 
diagnosis, follow up, and disease progression (N=100 hospital trusts) 
  Proactive case management Holistic needs assessment 
  diagnosis follow up  progression diagnosis follow up  progression 
Total 44% 45% 45% 25% 56% 46% 
LC service size at trust (N) 
Small (48) 44% 44% 42% 25% 50% 40% 
Medium (29) 52% 55% 55% 35% 62% 55% 
Large (23) 35% 35% 39% 13% 61% 48% 
χ² p value 0.7 0.5 0.6 0.3 0.7 0.6 
LCNS caseload at trust (N) 
Avg./Small (48) 40% 44% 38% 27% 50% 38% 
Large (52) 48% 46% 52% 23% 62% 54% 
χ² p value 0.5 0.9 0.3 0.7 0.4 0.2 
Anti-cancer treatment facilities at trust (N) 
No specialty (31) 45% 58% 48% 26% 48% 42% 
Surgical (25) 48% 48% 56% 16% 56% 44% 
Chemo. only (44) 41% 34% 36% 30% 61% 50% 
χ² p value 0.9 0.3 0.5 0.6 0.8 0.9 
Trust LC survival (N) 
Avg./High (34) 41% 41% 41% 27% 56% 41% 
Low* (66) 46% 47% 47% 24% 56% 49% 
χ² p value 0.8 0.7 0.7 0.8 1.0 0.6 
Proactive case management defined as regular contact with patient to identify issues early; holistic needs 
assessment defined as assessing the disease burden and patient needs as a whole. 
*Based on hazard ratio for death after diagnosis >1 compared with national mortality, adjusted for sex, age, 
stage, performance status and socioeconomic group. LC - lung cancer; LCNS - lung cancer nurse specialist; Avg. 
- average; Chemo. - chemotherapy; service size based on annual number of new LC patients at trust - Small 
(<175), Medium (175 <265), Large (≥265); LCNS caseload defined as number of LC patients per full-time 
equivalent LCNS relative to English median (188) - Avg./Small (≤188), or Large (>188).  % - Trusts where LCNS 
do not routinely offer the intervention as a percentage of trust type.  
 
3.2. Lung cancer service size and caseload  
Differences in the composition of LCNS workforce teams, patient contact, workload and MDT 
experiences according to the size of the lung cancer service and caseload were not statistically 
significant, with three exceptions (Table 2). A higher proportion (79.7%) of first contacts with 
patients before/at diagnosis were reported in medium sized services compared with small (71.7%) or 
large (72.7%) services (p=0.025). LCNS at hospital trusts with high caseloads were more likely to 
report no administrative support (p=0.048) and that they would challenge any MDT members 
(p=0.007) compared to those from lower caseload trusts. 
  
11 
 
Table 2: LCNS working practices according to the size of the lung cancer patient population at the 
hospital trust where they worked (N=230 LCNS) 
    LC service size of trust LCNS caseload at trust 
   
Total  
(230) 
Small  
(99) 
Medium  
(59) 
Large  
(72) 
χ² p: 
Avg./Small 
(108) 
Large  
(122) 
χ² p: 
Workforce features               
LCNS salary band composition at trust              
  Bands-6-7 37.0% 29.3% 47.5% 38.9%   35.2% 38.5%   
  Band-7-only 45.7% 52.5% 39.0% 41.7%   44.4% 46.7%   
  Band-8-inc. 17.4% 18.2% 13.6% 19.4% 0.202 20.4% 14.8% 0.528 
Timing of first contact relative to LC diagnosis α           
  Before/at 73.9% 71.7% 79.7% 72.2%   73.1% 74.6%   
  After 10.9% 16.2% 1.7% 11.1% 0.025 14.8% 7.4% 0.102 
Proportion patients first seen as emergency β 
  ≤20% 41.7% 40.4% 37.3% 47.2%   37.0% 45.9%   
  >20% 33.9% 38.4% 30.5% 30.6% 0.566 39.8% 28.7% 0.077 
Overtime & Administrative support 
Proportion of weekly hours working overtime γ           
  ≤10% 34.3% 29.3% 40.7% 36.1%   37.0% 32.0%   
  >10% ≤20% 38.3% 42.4% 30.5% 38.9%   38.0% 38.5%   
  >20% 25.2% 25.3% 27.1% 23.6% 0.555 23.1% 27.0% 0.678 
Administrative support per week 
  No support 63.5% 65.7% 61.0% 62.5%   58.3% 68.0%   
  Up to 10 Hrs 19.1% 21.2% 20.3% 15.3%   25.9% 13.1%   
  >10 Hrs 17.4% 13.1% 18.6% 22.2% 0.554 15.7% 18.9% 0.048 
MDT experiences               
Active MDT attendance δ               
  Yes 77.8% 82.8% 72.9% 75.0%   81.5% 74.6%   
  No 4.8% 5.1% 1.7% 6.9% 0.411 2.8% 6.6% 0.158 
Would challenge all members δ           
  Yes 51.7% 49.5% 47.5% 58.3%   44.4% 58.2%   
  No 30.9% 38.4% 27.1% 23.6% 0.188 39.8% 23.0% 0.007 
Find MDT intimidating or uncomfortable δ         
  Yes 19.1% 20.2% 23.7% 13.9%   20.4% 18.0%   
  No 63.5% 67.7% 50.8% 68.1% 0.209 63.9% 63.1% 0.750 
LCNS - lung cancer nurse specialist; LC - lung cancer; MDT - multidisciplinary team; Avg. - average; service size 
based on annual number of new LC patients at trust - Small (<175), Medium (175 <265), Large (≥265); LCNS 
caseload defined as number of LC patients per full-time equivalent LCNS relative to English median (188) - 
Avg./Small (≤188), or Large (>188). % - number of LCNS as a percentage of all LCNS responses; percentages may 
not add up to 100% because of missing data: p-values based on α-195 responses, β-174 responses, γ-225 
responses, δ-190 responses. 
 
3.3. Hospital trust treatment facilities and lung cancer patient survival  
LCNS workforce banding was associated with anti-cancer treatment facilities available at the trust 
(p=0.021), and a higher proportion of respondents from Band-7-only LCNS workforces were 
identified at trusts with higher average survival (p<0.001) (Table 3). Respondents from surgical trusts 
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were more likely to first see patients after diagnosis (21.6%) compared with chemotherapy trusts 
(4.3%) and trusts with no specialty (7.8%) (p<0.001). They were also less likely to see patients first 
presenting as an emergency (p<0.001). Trusts with higher survival had higher proportions of patients 
seen after diagnosis (p<0.001) and were less likely to see emergency presentations (p=0.022). 
Proportion of work done as overtime was not associated with trust treatment facilities, but 
administrative support was (p=0.002); the greatest proportion of respondents reporting no support 
was in trusts offering chemotherapy alone (70.7%), whilst over a quarter of respondents from 
surgical trusts had more than ten hours available per week. Active MDT attendance was higher in 
trusts with lower survival (p=0.002). LCNS at trusts with no specialty were much more likely to report 
they would challenge all MDT members (68.8%) compared with LCNS from surgical (43.2%) or 
chemotherapy (46.7%) trusts (p=0.005).  
  
13 
 
Table 3: LCNS working practices according to anti-cancer treatment facilities and lung cancer survival 
at the hospital trust where they worked (N=230 LCNS) 
    Anti-cancer treatment facilities LC survival 
   
Total  
(230) 
No 
specialty  
(64) 
Surgical 
(74) 
Chemo. 
only  
(92) χ² p: 
Avg./High  
(81) 
Low*  
(149) χ² p: 
Workforce features               
LCNS salary band composition at trust              
  Bands-6-7 37.0% 34.4% 25.7% 47.8%   17.3% 47.7%   
  Band-7-only 45.7% 43.8% 51.4% 42.4%   61.7% 36.9%   
  Band-8-inc. 17.4% 21.9% 23.0% 9.8% 0.021 21.0% 15.4% <0.001 
Timing of first contact relative to LC diagnosis α           
  Before/at 73.9% 81.3% 60.8% 79.3%   67.9% 77.2%   
  After 10.9% 7.8% 21.6% 4.3% <0.001 22.2% 4.7% <0.001 
Proportion patients first seen as emergency β 
  ≤20% 41.7% 45.3% 55.4% 28.3%   51.9% 36.2%   
  >20% 33.9% 39.1% 18.9% 42.4% <0.001 25.9% 38.3% 0.022 
Overtime & Administrative support 
Proportion of weekly hours working overtime γ           
  ≤10% 34.3% 25.0% 35.1% 40.2%   30.9% 36.2%   
  >10% ≤20% 38.3% 42.2% 35.1% 38.0%   33.3% 40.9%   
  >20% 25.2% 31.3% 24.3% 21.7% 0.375 30.9% 22.1% 0.252 
Administrative support per week 
  no support 63.5% 54.7% 62.2% 70.7%   67.9% 61.1%   
  Up to 10 Hrs 19.1% 34.4% 12.2% 14.1%   18.5% 19.5%   
  >10 Hrs 17.4% 10.9% 25.7% 15.2% 0.002 13.6% 19.5% 0.483 
MDT experiences                 
Active MDT attendance δ               
  Yes 77.8% 84.4% 73.0% 77.2%   79.0% 77.2%   
  No 4.8% 1.6% 9.5% 3.3% 0.060 11.1% 1.3% 0.002 
Would challenge all members δ           
  Yes 51.7% 68.8% 43.2% 46.7%   49.4% 53.0%   
  No 30.9% 17.2% 39.2% 33.7% 0.005 40.7% 25.5% 0.078 
Find MDT intimidating or uncomfortable δ         
  Yes 19.1% 18.8% 21.6% 17.4%   24.7% 16.1%   
  No 63.5% 67.2% 60.8% 63.0% 0.788 65.4% 62.4% 0.274 
*Based on hazard ratio for death after diagnosis >1 compared with national mortality, adjusted for sex, age, 
stage, performance status and socioeconomic group. LCNS - lung cancer nurse specialist; LC - lung cancer; MDT - 
multidisciplinary team; Chemo. - chemotherapy; Avg. - average; % - number of LCNS as a percentage of all LCNS 
responses; percentages may not add up to 100% because of missing data: p-values based on α-195 responses, β-
174 responses, γ-225 responses, δ-190 responses. 
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4. DISCUSSION 
We found variation in LCNS working practices across hospitals in England which was not directly 
explained by the size of the lung cancer service or the LCNS caseload. The treatment facilities at the 
trust and the trust’s lung cancer patient survival were associated with whether LCNS were more 
likely to initially see patients before/at diagnosis, whether they had more patients presenting as 
emergencies and to some extent with their MDT experience and workload. The majority of LCNS 
reported to undertake 10% or more of their work as overtime and reported no administrative 
support, the latter being highest at trusts with facilities for chemotherapy only. At most trusts the 
LCNS team offered all key interventions across the clinical care pathway, however, some trusts were 
unable to routinely deliver important aspects of the role at any point of the pathway, proactive case 
management and holistic needs assessment being not routinely offered at 17% and 9% of trusts 
respectively. Although variation existed and barriers were identified across hospital-trusts, we found 
no statistical evidence that the inability to offer key interventions was attributable to the particular 
trust factors assessed. Our results support recent survey findings of insufficient support and long 
hours for respiratory nurses (Yorke et al., 2017), whilst we provide specific insight on the LCNS role. 
4.1. Strengths and limitations 
Previous studies have provided important descriptions of LCNS workload and working practices in 
the UK (Baxter and Leary, 2011, Leary and Baxter, 2014, Leary et al., 2008, Leary et al., 2014), 
however no studies have linked survey responses with patient audit data to provide a 
comprehensive national picture. We used a large representative dataset of people with lung cancer 
(Rich et al., 2011), and captured the self-declared workload factors of the majority of the English 
LCNS workforce at the time of our survey; we estimate coverage of 76% of WTE LCNS positions 
across 70% of trusts. In our analyses, we assumed patients follow the pathway at the hospital where 
first seen; whilst we recognise that this is not always the reality, we considered it appropriate when 
modelling caseload as a workforce-dependent extension of service size and in defining lung cancer 
survival as reported by NLCA, particularly as LCNS act as a key-workers retaining responsibilities 
15 
 
beyond treatment. Caseload may, however, be under-estimated at tertiary centres. We do not 
report findings at patient level, and whilst we include anti-cancer facilities available as a factor in 
LCNS experiences, we do not make inference of the treatment pathways patients followed. Our 
findings offer considerations and cautions for nurses and other healthcare professionals to assist in 
shaping cancer services. 
For trusts not represented by survey respondents, we found no statistically significant differences 
associated with workforce composition, caseload, or anti-cancer treatment facilities, offering 
assurance that included trusts represented lung cancer services across England. We also assessed 
whether response rates for specific questions differed according to trust factors such as size or 
treatment facilities and found no major indication of response bias. Although the response was high, 
our sample of 230 LCNS at 105 trusts still resulted in small numbers within certain trust factor 
categories, so some difference may not have been statistically significant following chi-squared 
analysis. 
4.2. Features of LCNS workforces 
The salary band composition of the LCNS workforce was associated with anti-cancer treatment 
facilities at the trust and lung cancer survival, though a causal relationship was not tested; nurses of 
higher salary bands had greater representation in higher survival trusts, whilst less than 10% of 
respondents from trusts with chemotherapy facilities were represented by workforces that included 
Band 8 LCNS. Commissioning contracted hours at a specified band may not reflect the majority of 
LCNS hours provided but accountabilities or autonomies related to composition could influence 
team culture, yet in 2017 lung cancer had the lowest proportion of WTE Band 8 cancer nurse 
specialists compared to other cancers (Macmillan, 2017). Future study should aim to distinguish the 
potential contribution of workforce to localised differences in treatment uptake or survival 
outcomes.  
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The majority of LCNS respondents who stated seeing most of their patients after diagnosis were 
from surgical trusts and trusts with higher lung cancer survival, with a majority of LCNS from surgical 
trusts also seeing fewer patients as an emergency. Such proportions are likely a reflection of nurses 
working in tertiary or specialist centres who will see patients referred for treatment following 
diagnosis and thus will have a different relationship with patients compared to local hospital trusts. 
Irrespective, the prehabilitative role and support from the LCNS pre-treatment in advocating options 
is vital for the patient and NLCA makes a recommendation that at least 80% of people should have a 
LCNS present at diagnosis (RCP, 2017, Tod et al., 2015). LCNS teams can reduce inequities in access 
by offering assessments at the time of diagnosis for all patients wherever possible and ensuring 
continuity exists for patients referred on to specialist centres. 
4.3. Pressures on LCNS workforces 
In the UK, LCNS are assigned working hours for which they are expected to undertake clinical roles 
aligned to the salary banding and specialist nature of the role. Here, we find that most respondents 
reported working over an additional 10% of their contracted hours, particularly respondents at 
trusts with no treatment specialty. This demonstrates LCNS dedication to patients and their position 
whilst also highlights discrepancy in the expectations and reality of demands on specialist time; it is 
possible that the amount of overtime worked has partially masked the observed influence of 
caseload size. Hours additionally worked in efforts to maintain standards offered to the caseload 
should be carefully recorded so that optimal caseloads can be modelled, staffing issues can be 
predicted early, and safe workloads can be maintained. 
Many LCNS spend a large proportion of their time on administrative tasks, which does not make best 
use of specialist hours and can hinder completion of fuller assessment (Baxter and Leary, 2011, 
Richardson et al., 2011). LCNS from trusts with small caseloads or with surgical facilities were more 
likely to report availability of administrative support, although 64% of all respondents indicated no 
support. This confirms a need to help reduce the administrative burden on LCNS teams across 
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England, particularly apparent for those with high caseloads or working in chemotherapy trusts. 
Defined hours of weekly administrative support available to the LCNS team may reduce workload 
pressure and provide time for clinical, value-adding roles. 
4.4. Working practices of LCNS workforces 
Proactive case management is the recommended patient-centred approach for specialist nursing 
across disciplines (Baxter and Leary, 2011, DoH, 2007), and has been shown to reduce administrative 
burden and emergency admission rates post-diagnosis (Leary and Baxter, 2014). The importance of 
this work has also been described for patients paralysed by terror or blindsided by diagnosis (Carter-
Harris et al., 2015). We have shown that proactive case management and HNA were the 
interventions that most LCNS respondents were unable to routinely offer to patients across the 
pathway. Such findings are in agreement with nurse views of reactive care and work left undone 
(Leary et al., 2014), although we identified variation according to trust factors. Almost all nurses at 
medium sized services see patients before/at diagnosis yet many cannot offer HNA and most cannot 
offer proactive case management at this point. Similar findings were observed where caseloads were 
high, survival was low, and according to different anti-cancer facilities, suggesting a vulnerability to 
resource issues. To avoid potential gaps in care nurse-led services, such as follow-up clinics, and 
team remodelling to include a resource of support staff, offer strategies to facilitate proactive 
patient management and delivery of key LCNS roles (Brummell et al., 2015, Cox and Wilson, 2003, 
Moore et al., 2002, Moore et al., 2006).  
Characteristics of the LCNS role include acting as a ‘hub’ of the MDT due to their cancer specific 
expertise and unique knowledge of patient context that allows them to advocate patient wishes 
(Tod et al., 2015), with presence in MDTs now an explicit UK guideline (NICE, 2011). Non-attendance 
was greatest in surgical trusts and trusts with higher lung cancer survival, potentially due to 
workforce representation arrangements or additional commitments. Larger proportions of nurses 
who reported that they would not challenge all MDT members were associated with trusts that had 
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smaller caseloads or surgical facilities. These findings may be related to different hospital cultures, 
such as whether an LCNS chairs the meeting.  Similar associations were also found with nurses who 
felt uncomfortable or intimidated within MDT settings, which highlights an opportunity to improve 
MDT culture, inclusivity and engagement of all members as integrated care progresses across 
sectors (Harris et al., 2013, Punshon et al., 2017). 
5. Conclusion 
We provide evidence of variation in LCNS working practice across hospitals in England, highlighted 
according to interpretable factors that describe outcomes for patients, access to care or modes of 
service delivery. A number of LCNS-reported experiences appear to be associated with hospital 
factors. To ensure the safety of patients and quality of care, including access to appropriate lung 
cancer treatments, barriers to the delivery of LCNS expertise within an individual’s care pathway 
must be acknowledged and resolved, for instance through local refinement of clinics or supporting 
staff to enhance resource toward value adding activities. MDT culture also requires review in order 
to benefit from the unique knowledge LCNS offer, which can impact patient experience and 
outcomes. This study uses the combined voice of a large sample of English LCNS to provide 
opportunity for learning and implementation of service developments to support the provision of 
crucial LCNS roles; we offer recommendations regarding workforce features, support and inclusion, 
which could lead to gains for the local health economy and provide insight for other health services 
beyond the UK.  
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